News >

NICE Rejects Pembrolizumab for Urothelial Carcinoma

Gina Columbus
Published: Thursday, Mar 12, 2020

bladder The United Kingdom’s National Institute for Health and Care Excellence (NICE) has chosen not to recommend pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-containing chemotherapy.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication